Washington was supposed to lower drug prices in 2019. What happened?
Nearly everyone thought 2019 would be a big year for drug pricing. But neither Congress nor the White House enacted major policies to bring down costs.
Related Articles
U.S. FDA declines to approve Eli Lilly’s drug to treat eczema
The U.S. Food and Drug Administration (FDA) has declined to approve Eli Lilly’s drug to treat a type of skin disease due to certain findings…
Protecting children from poor air quality
3 in 4 parents are concerned about the impact of air quality problems on their child’s health. 2 in 3 parents report poor or unhealthy…
FDA Reviewers Say OTC Decongestant Doesn’t Work
But they acknowledge that taking the only shelf-accessible product off the market raises issues
Nestlé offloads peanut allergy therapy Palforzia to Stallergenes Greer
Nestlé announced Monday the divestment of its peanut allergy treatment business Palforzia (peanut allergen powder-dnfp) to Stallergenes Greer for an undisclosed sum. Nestlé kicked off…
From rapid cooling body bags to ‘prescriptions’ for AC, doctors prepare for a future of extreme heat
From body bags for rapid cooling to “prescriptions” for air conditioners, doctors are preparing for a future of extreme heat linked to climate change.
Hearing aids may slow mental decline in those at higher risk of dementia, study finds
New research ties hearing aids to slower cognitive decline in those at higher risk of dementia.
Johnson & Johnson sues to stop Medicare negotiation
Pharmaceutical giant Johnson & Johnson is the third drugmaker to sue the Biden administration over its new Medicare drug price negotiation program.
‘Doctors need to get on top of this’: GPT-4 displays bias in medical tasks
“GPT-4, being trained off of our own textual communication, shows the same — or maybe even more exaggerated — racial and sex biases as humans”…
Flagship, Pfizer team up in deal worth up to $7 billion
The new Pfizer partnership with Flagship will fund the development of up to 10 drug candidates.
STAT Virtual Event: The State of Biosimilars: What to Watch
Join STAT for a discussion of what’s next for biosimilars, and what key signals will indicate how they might be prescribed, or paid for.